Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;5(4):205-20.
doi: 10.1177/1756285612450936.

Current and emerging therapies in multiple sclerosis: a systematic review

Wanda Castro-Borrero  1 , Donna Graves, Teresa C Frohman, Angela Bates Flores, Paula Hardeman, Diana Logan, Megan Orchard, Benjamin Greenberg, Elliot M Frohman
Affiliations

Current and emerging therapies in multiple sclerosis: a systematic review

Wanda Castro-Borrero et al. Ther Adv Neurol Disord. 2012 Jul.

Abstract

Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.

Keywords: disease-modifying therapies; emerging therapies; fingolimod; glatiramer acetate; interferon β; multiple sclerosis; natalizumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Wanda Castro-Borrero has received speaker honoraria from the National Multiple Sclerosis Society, Multiple Sclerosis Association of America, Teva Neuroscience and Biogen Idec. Donna Graves has received speaker honoraria from Teva Neuroscience, Bayer Pharmaceuticals and Novartis. Teresa C. Frohman has received speaker honoraria from Teva Neuroscience and Biogen Idec. Angela Bates has received speaker honoraria from the National Multiple Sclerosis Society, Multiple Sclerosis Association of America, Teva Neuroscience and Biogen Idec. Paula Hardeman has nothing to disclose. Diana Logan has received speaker honoraria from Teva Neuroscience, and consulting fees from Biogen Idec, Teva Neuroscience, Bayer Pharmaceuticals and Acorda Therapeutics. Megan Orchard has nothing to disclose. Benjamin Greenberg has received honoraria from EMD Serono, American Academy of Neurology, Multiple Sclerosis Association of America, and National Multiple Sclerosis Society, consulting fees from Acorda, DioGenix, Greater Good Foundation, and grants from Amplimmune, Accelerated Cure Project and Guthy Jackson Charitable Foundation. Elliot Frohman has received speaker fees from Biogen Idec, Teva Neuroscience, Acorda Pharmaceuticals, and consulting fees from Biogen Idec, Teva Neurosciences, Abbott, Acorda Therapeutics, and Novartis.

References

    1. Achiron A., Gabbay U., Gilad R., Hassin-Baer R., Barak Y., Gornish M., et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50: 398–402 - PubMed
    1. Achiron A., Kishner I., Sarova-Pinhas I., Raz H., Faibel M., Stern Y., et al. (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61: 1515–1520 - PubMed
    1. Achiron A., Rotstein Z., Noy S., Mashiach S., Dulitzky M., Achiron R. (1996) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 243: 25–28 - PubMed
    1. Aharoni R., Teitelbaum D., Sela M., Arnon R. (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 94: 10821–10826 - PMC - PubMed
    1. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L. H., et al. (2008) Rituximab in relapsing–remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395–400 - PubMed

LinkOut - more resources